Assembly Biosciences Inc.
We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis del…
$20.09
-$0.48 (-2.33%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-16.76% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 153.5% YoY with margins expanding 142.5pp.
Negative free cash flow of -$41M. The business is consuming cash, not generating it.
16.6x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$75M
▲ +153.5% YoY
Net Income (TTM)
-$42K
▲ +84.8% YoY
Op. Margin
-11.75%
▲ +142.5pp YoY
ROIC
-3.08%
▲ +82.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▲ +19.5% YoY
Op. Cash Flow (TTM)
-$38M
▲ +19.6% YoY
Net Debt
-$318M
Net Cash Position
Cash & Equiv.
$320M
5Y CAGR: -1.8%
Continue Research
SourceComputed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Oct 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Assembly Biosciences (ASMB) overvalued?
At a P/E of 16.6, Assembly Biosciences (ASMB)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Assembly Biosciences scores 19/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Assembly Biosciences a high-quality business?+
Assembly Biosciences scores 19 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -11.8% operating margin and a -3.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Assembly Biosciences a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh ASMB's valuation and scores 19/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.